Leerink Partnrs Has Bullish Forecast for ACAD Q4 Earnings

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) – Leerink Partnrs boosted their Q4 2024 EPS estimates for shares of ACADIA Pharmaceuticals in a note issued to investors on Wednesday, January 29th. Leerink Partnrs analyst M. Goodman now expects that the biopharmaceutical company will post earnings of $0.12 per share for the quarter, up from their prior forecast of $0.10. The consensus estimate for ACADIA Pharmaceuticals’ current full-year earnings is $0.70 per share. Leerink Partnrs also issued estimates for ACADIA Pharmaceuticals’ FY2025 earnings at $0.75 EPS, FY2027 earnings at $1.44 EPS and FY2028 earnings at $2.13 EPS.

Other research analysts have also recently issued research reports about the stock. Guggenheim cut shares of ACADIA Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $23.00 to $20.00 in a research note on Friday, January 3rd. Raymond James reaffirmed a “market perform” rating on shares of ACADIA Pharmaceuticals in a research note on Thursday, October 10th. HC Wainwright reiterated a “buy” rating and set a $27.00 price objective on shares of ACADIA Pharmaceuticals in a research note on Thursday, November 7th. StockNews.com downgraded shares of ACADIA Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, November 14th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $28.00 price objective on shares of ACADIA Pharmaceuticals in a research note on Thursday, November 7th. Seven analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $25.25.

ACADIA Pharmaceuticals Trading Down 0.2 %

ACAD opened at $18.37 on Thursday. The company’s 50 day moving average is $17.40 and its 200 day moving average is $16.62. The company has a market cap of $3.06 billion, a price-to-earnings ratio of 23.55 and a beta of 0.37. ACADIA Pharmaceuticals has a 12-month low of $14.15 and a 12-month high of $27.94.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last announced its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $0.20 earnings per share for the quarter, beating analysts’ consensus estimates of $0.14 by $0.06. The business had revenue of $250.40 million during the quarter, compared to analyst estimates of $248.83 million. ACADIA Pharmaceuticals had a net margin of 13.83% and a return on equity of 25.83%. The company’s quarterly revenue was up 18.3% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.40) EPS.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Park Place Capital Corp purchased a new stake in ACADIA Pharmaceuticals during the third quarter worth $25,000. Values First Advisors Inc. bought a new position in shares of ACADIA Pharmaceuticals in the 3rd quarter worth $27,000. R Squared Ltd bought a new position in shares of ACADIA Pharmaceuticals in the 4th quarter worth $47,000. Quest Partners LLC lifted its stake in shares of ACADIA Pharmaceuticals by 42.3% during the 3rd quarter. Quest Partners LLC now owns 3,520 shares of the biopharmaceutical company’s stock worth $54,000 after purchasing an additional 1,047 shares during the last quarter. Finally, KBC Group NV boosted its position in ACADIA Pharmaceuticals by 67.0% during the fourth quarter. KBC Group NV now owns 5,093 shares of the biopharmaceutical company’s stock valued at $93,000 after purchasing an additional 2,044 shares in the last quarter. Institutional investors own 96.71% of the company’s stock.

Insider Activity

In related news, insider James Kihara sold 4,073 shares of ACADIA Pharmaceuticals stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $16.81, for a total transaction of $68,467.13. Following the completion of the sale, the insider now owns 19,863 shares in the company, valued at $333,897.03. This trade represents a 17.02 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, COO Brendan Teehan sold 10,329 shares of the company’s stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $16.81, for a total transaction of $173,630.49. Following the completion of the transaction, the chief operating officer now owns 62,105 shares in the company, valued at $1,043,985.05. This represents a 14.26 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 24,661 shares of company stock valued at $414,551 in the last ninety days. Insiders own 28.30% of the company’s stock.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.